TEL
AVIV, Israel, May 30, 2023
/PRNewswire/ -- BioLight (TASE: BOLT) is proud to report
it has signed a research collaboration agreement with Alexion
(AstraZeneca Rare Disease), focusing on exploring a groundbreaking
technology that utilizes natural tears for the potential diagnosis
of retinal diseases.
The study, financed by Alexion and BioLight, will evaluate a
screening technique (the "Technology") that analyzes components of
the tear film, an outer eye surface fluid layer. The Technology was
licensed from Harvard University and
will be utilized to analyze tear samples by one of the inventors,
Prof. Yifat Merbl, of the Weizmann Institute of Science. The study
will be conducted at the Tel Aviv Medical Center and led by Prof.
Anat Loewenstein, Chair of the
Ophthalmology department.
"Retinal disease affects the vision of hundreds of millions of
people worldwide. Early detection and treatment in the preliminary
stages of retinal eye disease can prevent vision loss for a
significant number of people. Finding an effective and simple tool
for diagnosing during the early stages of the disease's development
is a game changer. This is the objective of the experiment and
research, endeavoring to detect retinal disease through human tear
sampling," stated Yaacov Michlin,
CEO BioLight.
About BioLight Life Sciences Ltd.
BioLight manages and invests in companies with a primary focus
on bringing vital products to the market in the field of ocular
disease and novel treatments in Ophthalmology.
About Alexion, AstraZeneca Rare Disease
Alexion, AstraZeneca Rare Disease is a global biopharmaceutical
company focused on developing life-changing therapies for people
living with rare disorders.
Forward-looking statement:
The information, details, and BioLight's estimations contained
in this report about the collaboration, trial, and research
potential, commencement date of the study and its, execution
methods, the results of the study, the collaboration prospects
following it, and the approvals required in connection with the
aforementioned are "forward-looking information" as defined in the
Israeli Securities Law, 1968 which involves high uncertainty and is
based, among other things, on third parties and on various
variables over which the BioLight does not necessarily have
control, and as a result, it is possible that the aforementioned
information, details, and estimates, in practice, will not be
realized and/or will not be fully realized and/or will materialize
in a way that is fundamentally different from the initial
estimations or observations.
Contact:
Yaacov Michlin
+972509930707
yaacov@bio-light.co.il
Photo -
https://mma.prnewswire.com/media/2088064/BioLight_retinal.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolight-announces-a-joint-cooperation-agreement-with-alexion-astrazeneca-rare-disease-to-explore-an-innovative-technology-based-on-natural-tears-for-the-diagnosis-of-retinal-diseases-301837004.html
SOURCE BioLight Life Sciences Ltd.
